{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01996098\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ICTAN","nct_id":"NCT01996098","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ictan-nct01996098. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ICTAN","arms":[{"description":"Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months","label":"6-month icotinib","type":"EXPERIMENTAL"},{"description":"Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months","label":"12-month icotinib","type":"EXPERIMENTAL"},{"description":"No intervention","label":"Chemotherapy alone","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2024-02-15","type":"ACTUAL"},"conditions":["Lung Cancer"],"enrollment":{"count":251,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"6-month Icotinib","otherNames":["BPI-2009","Conmana"],"type":"DRUG"},{"name":"12-month icotinib","otherNames":["BPI-2009","Conmana"],"type":"DRUG"}],"last_update":"2024-09-05","lead_sponsor":"Sun Yat-sen University","official_title":"A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-Free Survival","timeFrame":"5 years after the last patient is randomized"}],"references":[{"citation":"Li N, Ou W, Cheng C, You J, Yang L, Chen FX, Liang Y, Yang Z, Wang BX, Chang ZH, Lin YB, Yang W, Xu F, Ding G, Chen XS, Hu R, Li S, Jiang H, Hu XX, Long H, Wang SY. Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Signal Transduct Target Ther. 2025 Aug 28;10(1):273. doi: 10.1038/s41392-025-02358-w.","pmid":"40866342","type":"DERIVED"}],"start_date":{"date":"2014-01-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation","url":"https://clinicaltrials.gov/study/NCT01996098"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ictan-nct01996098"}